Version 1
: Received: 28 September 2024 / Approved: 30 September 2024 / Online: 30 September 2024 (11:38:49 CEST)
How to cite:
Barghash, R.; Gemmati, D.; Awad, A. M.; Elbakry, M. M. M.; Tisato, V.; Awad, K.; Singh, A. V. Navigating the COVID-19 Therapeutic Landscape: Unveiling Novel Perspectives on FDA-Approved Medications, Vaccination Targets, and Emerging Novel Strategies. Preprints2024, 2024092409. https://doi.org/10.20944/preprints202409.2409.v1
Barghash, R.; Gemmati, D.; Awad, A. M.; Elbakry, M. M. M.; Tisato, V.; Awad, K.; Singh, A. V. Navigating the COVID-19 Therapeutic Landscape: Unveiling Novel Perspectives on FDA-Approved Medications, Vaccination Targets, and Emerging Novel Strategies. Preprints 2024, 2024092409. https://doi.org/10.20944/preprints202409.2409.v1
Barghash, R.; Gemmati, D.; Awad, A. M.; Elbakry, M. M. M.; Tisato, V.; Awad, K.; Singh, A. V. Navigating the COVID-19 Therapeutic Landscape: Unveiling Novel Perspectives on FDA-Approved Medications, Vaccination Targets, and Emerging Novel Strategies. Preprints2024, 2024092409. https://doi.org/10.20944/preprints202409.2409.v1
APA Style
Barghash, R., Gemmati, D., Awad, A. M., Elbakry, M. M. M., Tisato, V., Awad, K., & Singh, A. V. (2024). Navigating the COVID-19 Therapeutic Landscape: Unveiling Novel Perspectives on FDA-Approved Medications, Vaccination Targets, and Emerging Novel Strategies. Preprints. https://doi.org/10.20944/preprints202409.2409.v1
Chicago/Turabian Style
Barghash, R., Kareem Awad and Ajay Vikram Singh. 2024 "Navigating the COVID-19 Therapeutic Landscape: Unveiling Novel Perspectives on FDA-Approved Medications, Vaccination Targets, and Emerging Novel Strategies" Preprints. https://doi.org/10.20944/preprints202409.2409.v1
Abstract
Amidst the ongoing global challenge of the SARS-CoV-2 pandemic, the quest for effective antiviral medications remains paramount. This comprehensive review delves into the dynamic landscape of FDA-approved medications repurposed for COVID-19, categorized as antiviral and non-antiviral agents. Our focus extends beyond conventional narratives, encompassing vaccination targets, repurposing efficacy, clinical studies, innovative treatment modalities, and future outlooks. Unveiling the genomic intricacies of SARS-CoV-2 variants, including the WHO-designated Omicron variant, we explore diverse antiviral categories such as Fusion inhibitors, Protease inhibitors, Transcription inhibitors, Neuraminidase inhibitors, Nucleoside reverse transcriptase, and non-antiviral interventions like Importin α/β1-mediated nuclear import inhibitors, Neutralizing antibodies and convalescent plasma. Notably, Molnupiravir emerges as a pivotal player, now licensed in the UK. This review offers a fresh perspective on the historical evolution of COVID-19 therapeutics, from repurposing endeavors to the latest developments in oral anti-SARS-CoV-2 treatments, ushering in a new era of hope in the battle against the pandemic.
Keywords
Molnupiravir, SARS-CoV-2, Drug repurposing, Vaccines, Variant of concerns (VOC), Paxlovid
Subject
Public Health and Healthcare, Other
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
